S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
Wall Street Insider Makes Prediction about Hot A.I. Stock (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:NAMS

NewAmsterdam Pharma (NAMS) Stock Forecast, Price & News

$9.41
-0.41 (-4.18%)
(As of 09/22/2023 ET)
Compare
Today's Range
$8.57
$10.04
50-Day Range
$9.41
$12.02
52-Week Range
$7.52
$32.88
Volume
17,944 shs
Average Volume
86,146 shs
Market Capitalization
$767.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.67

NewAmsterdam Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
130.3% Upside
$21.67 Price Target
Short Interest
Healthy
0.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of NewAmsterdam Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.92) to ($1.41) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

451st out of 963 stocks

Pharmaceutical Preparations Industry

197th out of 458 stocks


NAMS stock logo

About NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NAMS Price History

NAMS Stock News Headlines

NewAmsterdam Pharma (NASDAQ: NAMS)
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
See More Headlines
Receive NAMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.

NAMS Company Calendar

Today
9/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NAMS
Fax
N/A
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.67
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$19.00
Forecasted Upside/Downside
+130.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-82,230,000.00
Pretax Margin
-80.05%

Debt

Sales & Book Value

Annual Sales
$102.74 million
Book Value
$6.26 per share

Miscellaneous

Free Float
79,521,000
Market Cap
$767.48 million
Optionable
Not Optionable
Beta
-0.35
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Michael Harvey Davidson FACC (Age 66)
    Facc., Facp., M.D., CEO, Pres, Exec. Board Member & Director
  • Dr. Johannes Jacob Pieter Kastelein FESC (Age 69)
    M.D., Ph.D., Founder, Chief Scientific Officer, Member of Exec. Board & Director
  • Ms. Louise Kooij (Age 47)
    Interim Chief Financial Officer
  • Mr. Douglas F. Kling (Age 50)
    Chief Operating Officer
  • Mr. Jim Jacobson
    Chief Legal Officer & Sec.
  • Dr. Marc Ditmarsch M.D. (Age 56)
    Chief Devel. Officer
  • Ms. Lina Gugucheva (Age 36)
    Chief Bus. Officer
  • Dr. Sheng Cui Ph.D.
    VP & Head of Chemistry Manufacturing and Controls (CMC)
  • Ms. Annie Neild
    VP & Head of Regulatory Affairs
  • Mr. William Jones Jr. (Age 59)
    M.B.A., Chief Commercial Officer













NAMS Stock - Frequently Asked Questions

Should I buy or sell NewAmsterdam Pharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NewAmsterdam Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NAMS shares.
View NAMS analyst ratings
or view top-rated stocks.

What is NewAmsterdam Pharma's stock price forecast for 2023?

4 Wall Street analysts have issued 1-year price objectives for NewAmsterdam Pharma's stock. Their NAMS share price forecasts range from $19.00 to $24.00. On average, they expect the company's stock price to reach $21.67 in the next twelve months. This suggests a possible upside of 130.3% from the stock's current price.
View analysts price targets for NAMS
or view top-rated stocks among Wall Street analysts.

How have NAMS shares performed in 2023?

NewAmsterdam Pharma's stock was trading at $10.90 on January 1st, 2023. Since then, NAMS stock has decreased by 13.7% and is now trading at $9.41.
View the best growth stocks for 2023 here
.

What is NewAmsterdam Pharma's stock symbol?

NewAmsterdam Pharma trades on the NASDAQ under the ticker symbol "NAMS."

Who are NewAmsterdam Pharma's major shareholders?

NewAmsterdam Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (12.84%), RA Capital Management L.P. (11.03%), Medicxi Ventures Management Jersey Ltd (3.52%), Affinity Asset Advisors LLC (0.12%), Monashee Investment Management LLC (0.12%) and Schonfeld Strategic Advisors LLC (0.07%).

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NewAmsterdam Pharma's stock price today?

One share of NAMS stock can currently be purchased for approximately $9.41.

How much money does NewAmsterdam Pharma make?

NewAmsterdam Pharma (NASDAQ:NAMS) has a market capitalization of $767.48 million and generates $102.74 million in revenue each year.

How can I contact NewAmsterdam Pharma?

NewAmsterdam Pharma's mailing address is TWO UNION SQUARE 601 UNION STREET SUITE 3200, SEATTLE WA, 98101. The official website for the company is www.newamsterdampharma.com. The company can be reached via phone at 352062971 or via email at max.nowicki@frazierhealthcare.com.

This page (NASDAQ:NAMS) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -